Atopic Dermatitis - The Dermatology Digest

EADV 2025 News: Investigational Temtokibart Performs Well in Phase 2b AD Study

September 17, 2025

Unpacking the Real-world Results From the AD-VISE Study With Dr. Melinda Gooderham

September 17, 2025

EADV 2025 News: Eczema Linked to Higher Risk of Suicidal Thoughts

September 16, 2025

AD Pipeline Watch: Rocatinlimab, an Anti-OX40 Monoclonal Antibody, Shows Sustained Safety, Efficacy

September 9, 2025

AD Pipeline Watch: CAGE Bio’s Topical CGB-500 Helps Patients Ditch Itch Early

September 6, 2025

Amlitelimab, Sanofi’s Anti-OX40L Antibody, Hits All Primary and Key Secondary Endpoints in Phase 3 AD Trial

September 4, 2025

Advertisement

Advertisement

Latest Issue

Latest Supplements

Upcoming Conferences

Advertisement

Advertisement

Digital Edition Archive